Common side effects of selpercatinib include dry mouth, hypertension, fatigue, increased aspartate aminotransferase level (AST), increased alanine aminotransferase level (ALT), increased glucose levels, and hypocalcemia, while pralsetinib additionally caused pain, constipation, and hematological toxicities such as decreased lymphocytes, neutrophils, and hemoglobin. The gene discussed is GPT; the disease is Hypocalcemia.